Fresenius, DE000FRE5EN2

Fresenius stock gains 0.68 percent pre-market to EUR 42.64

Published on 10/12/2026 at 08:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Fresenius stock is at EUR 42.64 pre-market at Lang & Schwarz on October 12, 2026. The price is up 0.68 percent versus the Xetra close of October 9, 2026.

Key points in brief

  • Fresenius stock at EUR 42.64 pre-market on October 12, 2026.
  • The price is plus 0.68 percent versus the Xetra close of October 9, 2026.
  • Fresenius lists its third-quarter report for November 4, 2026.
Fresenius SE – Fotorealistisch: Modernes Krankenhauszimmer mit Patientenmonitor bei Tageslicht
Fresenius SE & Co. KGaA (ISIN DE0005785604) ist ein internationaler Gesundheitskonzern mit Sitz in Bad Homburg. Das Unternehmen betreibt Krankenhäuser und entwickelt Arzneimittel und Infusionslösungen. Dieses Bild zeigt: Modernes Krankenhauszimmer mit Patientenmonitor bei Tageslicht, Illustration mit AI erstellt.

At 8:09 a.m. CEST on October 12, 2026, Fresenius stock stood at EUR 42.64 in pre-market trading at Lang & Schwarz. That was plus 0.68 percent, or EUR 0.29, versus the Xetra close of October 9, 2026, at EUR 42.35.

Pre-market price

Lang & Schwarz showed a bid of EUR 42.58 and an ask of EUR 42.71. The price indication places the stock above its most recent Xetra closing level as investors look toward the next regular German trading session. The further course from the Xetra open at 9:00 a.m. CEST is shown by the continuously updated real-time quote of Fresenius stock.

What matters today

Fresenius lists November 4, 2026, as the date for publication of its quarterly financial report, according to its EQS News calendar. A round-number level of EUR 45.00 is 5.54 percent above the Lang & Schwarz price. The latest reported P/E ratio was 15.40 as of October 9, 2026.

Market context: Market report DAX.

More news and analysis on Fresenius stock

Disclaimer...

en | DE000FRE5EN2 | FRESENIUS | boerse | 70296812 | bgmi